Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer

Key Points

• Oppenheimer initiated coverage with an "Outperform" rating and a $11.00 price target, implying about 118% upside from the prior close.
• Analyst views are mixed but skew positive: MarketBeat shows an average rating of "Moderate Buy" with an average price target of $9.13 (breakdown: 1 Strong Buy, 6 Buy, 1 Hold, 1 Sell).
• Savara shares traded at $5.04 (market cap ≈ $1.03B) and the clinical‑stage biopharma's lead candidate, Molgradex, is under regulatory review for autoimmune pulmonary alveolar proteinosis while the company reports negative EPS (analysts expect ~‑$0.48 for the fiscal year).

Analysts at Oppenheimer began coverage on shares of Savara (NASDAQ:SVRA - Get Free Report) in a report released on Friday. The brokerage set an "outperform" rating and a $11.00 price target on the stock. Oppenheimer's price objective would suggest a potential upside of 118.47% from the company's previous close.

Several other analysts also recently weighed in on SVRA. Wall Street Zen downgraded Savara from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research note on Tuesday. William Blair set a $10.00 price objective on shares of Savara in a research report on Monday, March 16th. Finally, HC Wainwright restated a "buy" rating on shares of Savara in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Savara has an average rating of "Moderate Buy" and an average price target of $9.13.

Savara Trading Up 1.9%

Shares of NASDAQ SVRA traded up $0.10 during trading hours on Friday, hitting $5.04. 100,560 shares of the company traded hands, compared to its average volume of 1,569,869. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -9.51 and a beta of 0.32. The company has a current ratio of 11.85, a quick ratio of 11.85 and a debt-to-equity ratio of 0.15. The company's 50 day moving average price is $5.51 and its 200 day moving average price is $5.33. Savara has a 12 month low of $1.89 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). On average, equities research analysts anticipate that Savara will post -0.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its position in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company's stock worth $60,000 after purchasing an additional 3,205 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock worth $37,000 after buying an additional 9,463 shares during the last quarter. Xponance LLC acquired a new stake in shares of Savara during the fourth quarter worth $66,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Savara during the third quarter worth $44,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Savara during the second quarter valued at $30,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.